clinical trial · NCT05360784
"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"
Ocular RednessBrimonidine tartrate ophthalmic solution 0.025% preservative-free formulationLumify® (brimonidine tartrate ophthalmic solution 0.025%)
brief summary
This is a multi-center, double-masked, randomized, active-controlled, parallel-group, efficacy and safety study that will enroll 386 participants at up to six clinical sites. Participants with ocular redness will be randomized to receive either brimonidine tartrate ophthalmic solution 0.025%, preservative-free formulation, or Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will be treated with study drug for approximately 4 weeks.
started
May 13, 2022
primary completion
Nov 23, 2022
completion
Nov 23, 2022
last updated
Aug 26, 2024
official title
The Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Preservative-Free Formulation With Lumify® 0.025% in Adult Subjects With Ocular Redness
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol